Press Releases

June 6, 2022
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
May 23, 2022
Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone
May 9, 2022
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 9, 2022
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
May 4, 2022
Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference
May 2, 2022
Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022
April 27, 2022
Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day
April 1, 2022
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
Displaying 1 - 10 of 15